Healthcare provider profile · identity verified

Thomas S Mullally, MD

Allopathic & Osteopathic Physicians|Internal Medicine · CROSWELL, MI · NPI 1629030879

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Thomas S Mullally, MD received $31.66 in general payments during 2025 across 2 reported records.

Viatris Specialty LLC accounted for 54.2% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 2 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.

GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$31.66

2 reported records · 2 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Viatris Specialty LLC	Unresolved — no canonical attribution shown	$17.15	54.2%	1	2025
GlaxoSmithKline, LLC.	Unresolved — no canonical attribution shown	$14.51	45.8%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$31.66	2

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
YUPELRI Normalized: yupelri	Drug	Viatris Specialty LLC	$17.15	1	2025
Source payment records 2025-03-06 · Viatris Specialty LLC · $17.15 · Open Payments source
TRELEGY ELLIPTA Normalized: trelegy ellipta	Drug	GlaxoSmithKline, LLC.	$14.51	1	2025
Source payment records 2025-09-04 · GlaxoSmithKline, LLC. · $14.51 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
TRELEGY ELLIPTA trelegy ellipta	2025	Trelegy Ellipta	2024	17 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference	2025	TRELEGY ELLIPTA open payments reported associated product	CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369	Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row	17	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	586	158
Levothyroxine Sodium	Levothyroxine Sodium	496	119
Amlodipine Besylate	Amlodipine Besylate	377	104
Losartan Potassium	Losartan Potassium	355	97
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	334	94
Omeprazole	Omeprazole	282	84
Metformin Hcl	Metformin Hcl	261	69
Metoprolol Tartrate	Metoprolol Tartrate	239	56
Atenolol	Atenolol	172	49
Furosemide	Furosemide	154	51
Simvastatin	Simvastatin	148	39
Tamsulosin Hcl	Tamsulosin Hcl	144	45
Meloxicam	Meloxicam	137	50
Pravastatin Sodium	Pravastatin Sodium	137	35
Sertraline Hcl	Sertraline Hcl	134	41
Jardiance	Empagliflozin	123	32
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	119	33
Famotidine	Famotidine	118	30
Potassium Chloride	Potassium Chloride	116	33
Prednisone	Prednisone	116	77
Eliquis	Apixaban	114	27
Baclofen	Baclofen	108	41
Pantoprazole Sodium	Pantoprazole Sodium	108	22
Metoprolol Succinate	Metoprolol Succinate	105	32
Allopurinol	Allopurinol	98	27
Hydrochlorothiazide	Hydrochlorothiazide	97	32
Lovastatin	Lovastatin	95	22
Lisinopril	Lisinopril	94	27
Pioglitazone Hcl	Pioglitazone Hcl	93	25
Alprazolam	Alprazolam	88	27
Fluticasone Propionate	Fluticasone Propionate	87	34
Citalopram Hbr	Citalopram Hydrobromide	86	22
Azithromycin	Azithromycin	80	64
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	80	20
Montelukast Sodium	Montelukast Sodium	79	25
Rosuvastatin Calcium	Rosuvastatin Calcium	72	22
Trazodone Hcl	Trazodone Hcl	68	23
Cephalexin	Cephalexin	64	40
Gabapentin	Gabapentin	64	19
Tramadol Hcl	Tramadol Hcl	62	12
Clopidogrel	Clopidogrel Bisulfate	60	19
Finasteride	Finasteride	55	15
Ibuprofen	Ibuprofen	49	17
Paroxetine Hcl	Paroxetine Hcl	49	11
Hydralazine Hcl	Hydralazine Hcl	45	12
Glimepiride	Glimepiride	44	15
Ciprofloxacin Hcl	Ciprofloxacin Hcl	43	31
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	42	17
Bupropion Xl	Bupropion Hcl	39	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	39	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	39	suppressed
Amoxicillin	Amoxicillin	38	29
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	37	12
Levofloxacin	Levofloxacin	37	29
Triamcinolone Acetonide	Triamcinolone Acetonide	37	22
Isosorbide Mononitrate Er	Isosorbide Mononitrate	36	11
Cefprozil	Cefprozil	35	20
Donepezil Hcl	Donepezil Hcl	35	suppressed
Glipizide	Glipizide	34	12
Buspirone Hcl	Buspirone Hcl	33	suppressed
Meclizine Hcl	Meclizine Hcl	33	17
Venlafaxine Hcl Er	Venlafaxine Hcl	33	suppressed
Synthroid	Levothyroxine Sodium	32	suppressed
Fentanyl	Fentanyl	30	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	27	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	27	suppressed
Alendronate Sodium	Alendronate Sodium	26	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	26	18
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	26	23
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	26	suppressed
Enalapril Maleate	Enalapril Maleate	26	suppressed
Warfarin Sodium	Warfarin Sodium	25	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	24	suppressed
Ropinirole Hcl	Ropinirole Hcl	24	suppressed
Ventolin Hfa	Albuterol Sulfate	24	suppressed
Celecoxib	Celecoxib	23	suppressed
Spironolactone	Spironolactone	23	suppressed
Terazosin Hcl	Terazosin Hcl	22	suppressed
Toujeo Max Solostar	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Enalapril-Hydrochlorothiazide	Enalapril/Hydrochlorothiazide	21	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	20	14
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	20	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	20	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Glipizide Er	Glipizide	18	suppressed
Januvia	Sitagliptin Phosphate	18	suppressed
Primidone	Primidone	18	suppressed
Propranolol Hcl	Propranolol Hcl	18	suppressed
Carvedilol	Carvedilol	17	suppressed
Clonazepam	Clonazepam	17	suppressed
Morphine Sulfate Er	Morphine Sulfate	17	suppressed
Oxcarbazepine	Oxcarbazepine	17	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Amiodarone Hcl	Amiodarone Hcl	16	suppressed
Levetiracetam	Levetiracetam	16	suppressed
Lorazepam	Lorazepam	16	suppressed
Novolin N	Insulin Nph Human Isophane	16	suppressed
Verapamil Er	Verapamil Hcl	16	suppressed
Acyclovir	Acyclovir	15	suppressed
Duloxetine Hcl	Duloxetine Hcl	15	suppressed
Nifedipine Er	Nifedipine	15	suppressed
Nitroglycerin	Nitroglycerin	15	suppressed
Fluconazole	Fluconazole	14	suppressed
Levemir Flexpen	Insulin Detemir	14	suppressed
Constulose	Lactulose	13	suppressed
Ezetimibe	Ezetimibe	13	suppressed
Gemfibrozil	Gemfibrozil	13	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Xarelto	Rivaroxaban	13	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	13	suppressed
Zonisamide	Zonisamide	13	suppressed
Clotrimazole	Clotrimazole	12	suppressed
Comfort Ez Pen Needle	Pen Needle, Diabetic	12	suppressed
Metformin Hcl Er	Metformin Hcl	12	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	12	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	12	suppressed
Topiramate	Topiramate	12	suppressed
Clonidine Hcl	Clonidine Hcl	11	suppressed
Ozempic	Semaglutide	11	suppressed
Valacyclovir	Valacyclovir Hcl	11	suppressed
Varenicline Tartrate	Varenicline Tartrate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$31.66 · 2 records	Viatris Specialty LLC	TRELEGY ELLIPTA, YUPELRI	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error